Impact of Helicobacter pylori resistance to clarithromycin on the efficacyof the omeprazole-amoxcillin-clarithromycin therapy

Citation
J. Tankovic et al., Impact of Helicobacter pylori resistance to clarithromycin on the efficacyof the omeprazole-amoxcillin-clarithromycin therapy, ALIM PHARM, 15(5), 2001, pp. 707-713
Citations number
37
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Pharmacology,"da verificare
Journal title
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
ISSN journal
0269-2813 → ACNP
Volume
15
Issue
5
Year of publication
2001
Pages
707 - 713
Database
ISI
SICI code
0269-2813(200105)15:5<707:IOHPRT>2.0.ZU;2-X
Abstract
Background: Helicobacter pylori resistance to clarithromycin is relatively frequent in France and is assumed to be the main cause of failure of the pr oton pump inhibitor-amoxicillin-clarithromycin (proton pump inhibitor-AC) t herapy, which is the first-line regimen in France. Aim: To determine the respective effects of clarithromycin primary and seco ndary resistances on efficacy of the proton pump inhibitor-AC regimen and t o determine whether failures are associated with persistence of the same st rain or with emergence of a new one. Methods: A total of 123 H. pylori-infected patients were treated for 7 days with omeprazole 20 mg b.d., amoxicillin 1 g b.d., and clarithromycin 500 m g b.d. Eradication was assessed by breath test in 102 patients. Minimal inh ibitory concentrations of clarithromycin were determined by E-test. Strain genotyping was performed by random amplified polymorphic DNA. Results: The pre-treatment and post-treatment prevalences of clarithromycin resistance were 19% (23 out of 123) and 69% (nine out of 13), respectively , The rates of eradication were 68% (69 out of 102), 79% (67 out of 85), an d 12% (two out of 17) for all, susceptible and resistant strains, respectiv ely. The post-treatment isolate was available for six patients with a susce ptible pretreatment isolate and a persistent infection. Resistance emerged in two patients and was associated with persistence of the pre-treatment st rain in one and with selection of a new strain in the other. Conclusions: In our hospital, failures of the proton pump inhibitor-AC ther apy are related to both clarithromycin primary and secondary resistances, b ut the emergence of secondary resistance does not explain all of the failur es in the initial clarithromycin-susceptible group. In that group a new str ain can emerge after failure.